What are the weight‑based pediatric dosing recommendations for oseltamivir (Tamiflu) for treatment and post‑exposure prophylaxis, including adjustments for infants and renal impairment?

Tamiflu (Oseltamivir) Pediatric Dosing

For children ≥12 months, use weight-based dosing (30–75 mg twice daily for treatment, once daily for prophylaxis); for infants <12 months, use age-based mg/kg dosing (3–3.5 mg/kg); and for preterm infants, use postmenstrual age-based dosing (1.0–3.0 mg/kg) to avoid toxic accumulation from immature renal function. 1, 2

---

Treatment Dosing (5 days, twice daily)

Children ≥12 months (weight-based categorical dosing)

• ≤15 kg (≤33 lb): 30 mg (5 mL of 6 mg/mL suspension) twice daily 1, 3
• >15–23 kg (>33–51 lb): 45 mg (7.5 mL) twice daily 1, 3
• >23–40 kg (>51–88 lb): 60 mg (10 mL) twice daily 1, 3
• >40 kg (>88 lb): 75 mg (12.5 mL) twice daily 1, 3

Term infants <12 months (age-based mg/kg dosing)

• 0–8 months: 3 mg/kg per dose twice daily 1, 3
• 9–11 months: 3.5 mg/kg per dose twice daily 1, 3

Preterm infants (postmenstrual age-based dosing)

• <38 weeks postmenstrual age: 1.0 mg/kg twice daily 4, 1
• 38–40 weeks postmenstrual age: 1.5 mg/kg twice daily 4, 1
• >40 weeks postmenstrual age: 3.0 mg/kg twice daily 4, 1

Critical pitfall: Do NOT use the weight-based categorical dosing (≤15 kg = 30 mg) for infants <12 months; that scheme applies only to children ≥12 months. 1, 2 Do NOT apply term-infant dosing to preterm infants—postmenstrual age-based dosing is mandatory to prevent toxic drug concentrations from immature renal clearance. 4, 1

---

Prophylaxis Dosing (10 days, once daily)

Children ≥12 months (same weight categories, once daily)

• ≤15 kg: 30 mg once daily 1, 3
• >15–23 kg: 45 mg once daily 1, 3
• >23–40 kg: 60 mg once daily 1, 3
• >40 kg: 75 mg once daily 1, 3

Infants 3–11 months

• 3 mg/kg once daily for 10 days 1, 3

Infants <3 months

• Prophylaxis is NOT recommended unless the clinical situation is judged critical, due to limited safety data. 4, 1

---

Renal Impairment Adjustments

Creatinine clearance 10–30 mL/min

• Treatment: Reduce to once daily dosing (instead of twice daily) for 5 days. For example, 75 mg once daily or 30 mg once daily. 4, 1, 3
• Prophylaxis: Either 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses). 4, 1, 3

Critical pitfall: Failure to adjust dosing when creatinine clearance is <60 mL/min can lead to drug accumulation and toxicity. 1

---

Formulation, Measurement, and Administration

Oral suspension (preferred for infants and young children)

• Concentration: 6 mg/mL after reconstitution 1, 3
• Measurement device: Use a calibrated 3-mL or 5-mL oral syringe for infants; household spoons must NOT be used. 1, 2
• Compounding option: If commercial suspension is unavailable, pharmacies can compound a 6 mg/mL suspension by opening capsules and mixing contents with simple syrup or Ora-Sweet SF per package instructions. 1

Capsules (for older children who can swallow)

• Available in 30 mg, 45 mg, and 75 mg strengths 1
• Capsules may be opened and mixed with sweetened liquid if needed 1

Administration with food

• Take with food to markedly reduce nausea and vomiting, which occur in approximately 10–15% of patients. 1, 5
• Gastrointestinal side effects are mild, transient, and resolve within 1–2 days. 5

---

Timing and Clinical Benefits

Optimal initiation window

• Start within 48 hours of symptom onset for maximal benefit 1, 3, 5
• Starting within 12–24 hours provides substantially greater effectiveness—reduces illness duration by an additional 74.6 hours compared to initiation at 48 hours 5

Clinical benefits of early treatment

• Reduces illness duration by approximately 1–1.5 days (26–36% reduction) 1, 5
• Decreases severity of cough, nasal congestion, and fever 1
• Lowers risk of secondary complications, especially acute otitis media, by approximately 44% 1, 5

Complete the full 5-day course

• Do NOT stop therapy early even if symptoms improve before day 5; completing the full course ensures adequate viral suppression and helps prevent resistance. 1

---

Special Populations and Expert Consultation

FDA approval and off-label use

• FDA-approved for treatment in children as young as 2 weeks of age 1, 3
• May be used from birth (including preterm infants) when anticipated benefits outweigh risks, based on early pharmacokinetic data 1

Extremely preterm infants (<28 weeks postmenstrual age)

• Consult a pediatric infectious disease specialist before initiating therapy 1, 2

Infants <1 year with low body weight or neonates

• Consult a pediatric infectious disease specialist when considering oseltamivir 4, 2

---

Common Dosing Pitfalls to Avoid

• Do NOT apply weight-based categorical dosing (≤15 kg = 30 mg) to infants <12 months 1, 2
• Do NOT use term-infant dosing for preterm infants; postmenstrual age-based dosing is required 4, 1
• Do NOT confuse treatment dosing (twice daily) with prophylaxis dosing (once daily) 1, 2
• Do NOT round doses inappropriately; calculate the exact mg/kg dose and measure precisely 1
• Do NOT use household spoons for measurement; always use a calibrated oral dosing device 1, 2
• Do NOT delay antiviral therapy while awaiting laboratory confirmation during influenza season; clinical judgment is sufficient 1